|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating Expenses: | |||||
| Research and development | |||||
| Selling, general and administrative (including $432,000 and $230,000 of stock compensation during the years ended December 31, 2025 and 2024, respectively) | |||||
| Total Operating Expenses | |||||
| Loss from Operations | |||||
| Other Income (Expense) | |||||
| Interest income | |||||
| Interest expense | |||||
| Loss on initial recognition of Greenshoe Rights liability | |||||
| Change in fair value of Greenshoe Rights liability | |||||
| Change in fair value of warrant liability | |||||
| Gain on extinguishment of share settled debt | |||||
| Share Settled Debt | |||||
| Total gain on extinguishment of share settled debt | |||||
| Unrealized gain on short-term investments | |||||
| Gain on settlement of vendor payable | |||||
| Other | |||||
| Total Other Income (Expense), Net | |||||
| Net Loss | |||||
| Dividend on Series L Preferred Stock | |||||
| Deemed dividend | |||||
| Net Loss attributable to common stockholders’ | |||||
| Net Loss Per Share - Basic | |||||
| Net Loss Per Share - Diluted | |||||
| Weighted average common shares outstanding - basic | |||||
| Weighted average common shares outstanding - diluted | |||||
Loading...
